Quanqi Biotechnology

Quanqi Biotechnology is a Shanghai-based biopharmaceutical company dedicated to developing next-generation, off-the-shelf cell therapies using induced pluripotent stem cell (iPSC) technology. Founded by industry veterans with experience at leading cell therapy firms like Fate Therapeutics and Kite Pharma, the company focuses on creating standardized, scalable, and high-potency immune cell products, including iPSC-derived Natural Killer (iNK) and T (iT) cells. Their proprietary platform aims to overcome the limitations of autologous CAR-T therapies, such as high production costs and long manufacturing lead times. Quanqi's pipeline is primarily directed toward treating both hematological malignancies and challenging solid tumors. The company has successfully secured significant venture capital funding to advance its candidates through pre-clinical development and toward clinical trials. By leveraging advanced gene editing and iPSC differentiation techniques, Quanqi seeks to provide more affordable and accessible immunotherapy options for cancer patients globally.